Eloxx Pharmaceuticals, INC Form 4 insider transactions
Insider transactions: buys and sells by directors, officers and ten percent owners, filed within two business days of the trade.
NASDAQ
Domicilium Real Estate Fund III LP reported the conversion of pre-funded warrants into 600,000 shares of Eloxx Pharmaceuticals common stock.
NASDAQ
Director Stephen W. Webster was granted 13,587 stock options in Eloxx Pharmaceuticals as part of standard equity compensation.
NASDAQ
Director Alan Edmund Walts was granted 8,590 stock options in Eloxx Pharmaceuticals as part of a compensation arrangement.
NASDAQ
Director Nina S. Kjellson was granted 13,587 stock options in Eloxx Pharmaceuticals, Inc. as part of a standard equity compensation plan.
NASDAQ
Eloxx Pharmaceuticals CEO Sumit Aggarwal has been granted 328,833 stock options following the satisfaction of performance-based vesting conditions.
NASDAQ
Director Steven D. Rubin was granted 4,018 stock options in Eloxx Pharmaceuticals, Inc. as part of a compensation arrangement.
NASDAQ
Domicilium Real Estate Fund III LP reports an exchange of common stock for pre-funded warrants in Eloxx Pharmaceuticals, Inc.
NASDAQ
Major shareholder Coastlands Capital LP has exchanged 1.25 million shares of Eloxx Pharmaceuticals common stock for pre-funded warrants.
NASDAQ
Director Steven D. Rubin acquired common stock through the vesting of restricted stock units and was granted new stock options.
NASDAQ
CEO Sumit Aggarwal disclosed multiple stock option exercises and equity grants in a recent SEC Form 4 filing.
NASDAQ
Director Alan Walts acquired 1,875 shares of Eloxx Pharmaceuticals common stock through the vesting of restricted stock units.
NASDAQ
Eloxx Pharmaceuticals director Sumit Aggarwal acquired 30,000 shares of common stock through the vesting of restricted stock units on January 24, 2025.
NASDAQ
Director Steven D. Rubin acquired 3,750 shares of Eloxx Pharmaceuticals common stock through the vesting of restricted stock units.
NASDAQ
Director Lindsay Androski acquired 3,750 shares of Eloxx Pharmaceuticals common stock through the vesting of restricted stock units.
NASDAQ
Director Alan Walts of Eloxx Pharmaceuticals exercised stock options and received restricted stock units, resulting in a change in his beneficial ownership of the company's stock.